PA5-47239

antibody from Invitrogen Antibodies

Targeting: KLK6 Bssp, Klk7, neurosin, PRSS18, PRSS9

Western blot (Recommended by provider)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-47239

Provider

Invitrogen Antibodies

Product name

Kallikrein 6 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) Kallikrein 3, rhKallikrein 5, rhKallikrein 11, rhKallikrein 13, rhKallikrein 14, and rhKallikrein 15 is observed. Reconstitute at 0.2 mg/mL in sterile PBS.

Reactivity

Human

Host

Goat

Isotype

IgG

Vial size

100 µg

Concentration

0.2 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Altered human oligodendrocyte heterogeneity in multiple sclerosis.

Jäkel S, Agirre E, Mendanha Falcão A, van Bruggen D, Lee KW, Knuesel I, Malhotra D, Ffrench-Constant C, Williams A, Castelo-Branco G
Nature 2019 Feb;566(7745):543-547

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Extended Figure4 Validation of novel OL sub-cluster markers and regional OL subpopulation distribution in human Ctr brain. a , Violin plots showing SOX6 , RTN4 (NOGOA) and OLIG2 normalized expression counts in different OL subpopulations (n=number of nuclei in Ctr nOPC=273, nCOP=153, ImOLG=81, nOligo1=952, nOligo2=388, nOligo3=82, nOligo4=724, nOligo5=393, nOligo6=991). Violin plots are centered around the median with interquartile ranges, with shape representing cell distribution. b , Colocalization of SOX6 and OLIG2 as a marker for OPCs (scale bar: 20um). c , Colocalization of OPALIN and OLIG2 as a marker for Oligo6 (scale bar: 20um). d , Colocalization of KLK6 and OLIG1/2 as a marker for Oligo5. e , Colocalization of SOX6, NOGOA and OLIG2. SOX6+OLIG2+NOGOA- cells (upper panel) are OPCs, NOGOA+OLIG2+SOX6- cells are mature OL (scale bar: 10um). f , OPALIN staining of a Ctr brain section (scale bars: 5mm, inlay: 300um). g , OPALIN+ Oligo6 in different bins of 300um increments from the GM/WM border (scale bar:50um, n=3 different Ctr and MS individuals with NAWM and lesions, ANOVA, data are displayed as mean +- SEM). h , Combined OPALIN and KLK6 staining of another human Ctr brain block (scale bar: 5mm, inlays: 50um). In b - e experiments were independently performed in 2 batches. i , Validation of novel OL mRNA markers in combination with OLIG1/2 IHC. BCAN (top left), CLDND1 (top right), KLK6 (bottom left) and CDH20 (bottom right). Red arrowheads: marker+/OLIG1/

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Extended Figure8 Validation of skewed MS heterogeneity and OL gene expression profiling in Ctr and NAWM. a , Validation of BCAN-expressing OPCs in combination with OLIG1/2 IHC. Red arrowhead: BCAN +/OLIG1/2+ OPC, blue arrowhead: BCAN-/OLIG1/2+ OL (scale bar: 20um) and tSNE overlay of BCAN expression in the snRNA-seq dataset in Ctr and MS, (scale bar: 20um, data displayed as mean+-SEM, n=4 samples from different control individuals, n=6 NAWM samples and n=5 MS lesion samples from different MS patients, ANOVA. b , KLK6-expressing OL in Ctr WM, NAWM and MS lesions (scale bar: 50um, data displayed as mean+-SEM, n=4 samples from different Ctr individuals and n=5 different MS individuals, ANOVA) and tSNE overlay of KLK6 expression in the Ctr and MS snRNA-seq dataset. c , Violin plots showing the normalized expression counts of genes enriched in ImOLG in the snRNA-seq dataset (nOPC=352, nCOP=242, nImOLG=207, nOligo1=1129, nOligo2=1839, nOligo3=775, nOligo4=1579, nOligo5=1167, nOligo6=1484). Violin plots are centered around the median with interquartile ranges, with shape representing cell distribution. d , MRF IHC in Ctr WM, NAWM and MS lesions (scale bar: 50um, data displayed as mean+-SEM, n=6 samples from different control individuals, and n=7 different MS patients, ANOVA) and tSNE overlay of MYRF expression in the snRNA-seq dataset. e, tSNE overlay of MBP expression in the Ctr and the MS snRNA-seq dataset (n=4037 OL in Ctr and n=4737 OL in MS). f , Western blot of